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A b s t r a c t
Background: Heart failure affects patients with normal left ventricular systolic function (heart failure with preserved ejection 
fraction [HFPEF]) and those with reduced ejection fraction (HFREF). The treatment of HFPEF remains an unresolved issue.
Aim: We sought to determinate the relationship between inflammatory markers and left ventricular diastolic dysfunction 
(LVDD) in a family-based population study.
Methods: A total of 303 participants from the general population (55% women, median age 49 years and 45% men, median 
age 40 years) underwent echocardiography and measurement of serum inflammatory markers: C-reactive protein (CRP), 
myeloperoxidase (MPO), and interleukin 6 (IL-6). 
Results: Serum IL-6 concentration correlated with peak transmitral late diastolic velocity (A) and pulmonary vein systolic-to-di-
astolic velocity (S/D) ratio (p < 0.01). Moreover, a significant correlation between IL-6 concentration and E/A ratio and early 
diastolic peak velocities of the mitral annulus displacement (E’) was observed. The association of IL-6 concentration and peak 
transmitral early diastolic velocities (E) and the E/E’ ratio (p < 0.05) was noted in men. In addition, the CRP concentration 
was shown to have an effect on E/A ratio in women (p < 0.05). A significant correlation between the CRP concentration and 
S/D ratio was observed both in women (p < 0.01) and men (p < 0.05). No significant correlation was found between the 
level of MPO and LVDD parameters. Additionally, only one predictive model was identified; E’ was found to be dependent 
on IL-6, age, and heart rate in men (p < 0.001, R2 = 0.611). 
Conclusions: The above results suggest that inflammation may lead to the onset of LVDD, probably via vascular endothelial  
dysfunction.
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INTRODUCTION
Heart failure is a disease that affects patients with normal 
left ventricular systolic function (so-called heart failure with 
preserved ejection fraction [HFPEF]) and those with reduced 
ejection fraction (HFREF) [1]. In the presence of heart failure 
symptoms, the diagnosis of HFPEF requires the occurrence 
of left ventricular ejection fraction (LVEF) of at least 50%, 
elevated levels of natriuretic peptides (B-type natriuretic 
peptide > 35 pg/mL, and/or N-terminal pro–B-type natriu-
retic peptide [NT-proBNP] > 125 pg/mL), and at least one 
additional criterium: relevant structural heart disease or left 
ventricular diastolic dysfunction (LVDD) [1]. We should bear 
in mind that LVDD may occur as an isolated disease in over 
20% of the European population [2, 3]. Moreover, LVDD may 
precede systolic dysfunction, which means that patients with 
HFREF often also have LVDD of varying severity [1, 4]. Typical 
symptoms of HFPEF are caused by increased filling pressure 
resulting from impaired relaxation and disturbed compliance 
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of the left ventricle. Numerous clinical trials have demon-
strated that pharmacotherapy had a positive effect in reduc-
ing morbidity and mortality only in patients with HFREF. The 
treatment of isolated HFPEF remains an unresolved issue [5]. 
According to the latest guidelines of the American Heart 
Association (AHA) and the American College of Cardiology 
(ACC), HFPEF treatment should focus on hypertension, main-
taining sinus rhythm, preventing tachycardia and myocardial 
ischaemia, and reducing venous pressure [6, 7].
Because hypertension affects up to 60% of patients 
with HFPEF, the guidelines set by the AHA and ACC place 
particular emphasis on antihypertensive treatment in such 
patients [7, 8]. Normalisation of arterial pressure helps lower 
left ventricular late diastolic pressure and left atrial pressure, 
improve left ventricular relaxation, reduce oxygen demand, 
improve perfusion, and reduce myocardial ischaemia.
The pathogenesis of hypertension is multifactorial and 
the course of the disease is associated with disturbed interac-
tion between cardiac, vascular, renal, endocrine, genetic, and 
environmental factors. Experimental and clinical tests suggest 
that the primary changes in the immune system may have 
an effect on the inflammatory response of the arterial walls, 
leading to elevated blood pressure and subsequent hyperten-
sion [9–13]. Inflammation is associated with an increase in 
the serum concentration of many proteins and compounds, 
such as C-reactive protein (CRP), fibrinogen, interleukin (IL), 
especially IL-6 and IL-8, and tumour necrosis factor (TNF) [14, 
15]. Chronic inflammation leads to endothelial dysfunction 
[16, 17]. The endothelium lining of all blood vessels is a key 
element in regulating vascular resistance [18].
The purpose of this study was to determinate the re-
lationship between inflammatory markers and LVDD in 
a family-based population study. 
METHODS
Study participants
The study included participants of the Polish part of a Euro-
pean research project on inherited hypertension called the 
European Project on Genes in Hypertension (EPOGH). The 
study was approved by the Ethical Committee of the Jagiel-
lonian University Medical College. All clinical investigations 
were conducted according to the principles expressed in the 
Declaration of Helsinki. The study used the family structure 
and was conducted in the years 1999–2008. The general 
population families were selected from among the inhabitants 
of the town and municipality of Niepolomice. In the years 
2012–2014, adult members of the previously tested families 
were re-examined. The subjects were asked to complete 
a questionnaire providing information on their demographic 
data, socioeconomic status, comorbidities, as well as the 
medicines and substances they had taken. The following 
parameters were measured in each participant: height, body 
weight, and conventional blood pressure using the average of 
five consecutive readings obtained during the visit. Hyperten-
sion was defined as a blood pressure of at least 140 mmHg 
systolic or 90 mmHg diastolic (average of five consecutive 
auscultatory readings at the examination centre). Body mass 
index was measured as weight in kilograms divided by the 
square of height in metres. In addition, biochemical markers 
in serum were taken to determine the levels of NT-proBNP 
(enzyme immunofluorescence assay), CRP (highly sensitive 
immunonefelometric assay), myeloperoxidase (MPO), and 
IL-6 (enzyme-linked immunosorbent assay, R&D Systems, 
Minneapolis, MN, USA). 
Echocardiography
All participants refrained from smoking, exercising, and 
drinking alcohol at least 3 h before the echocardiography 
examination. 
An experienced physician performed the echocardiog-
raphy examination using interfaced Vivid7 Pro device (GE 
Vingmed, Horten, Norway) with a 2.5–3.5-MHz phased-array 
probe. All the subjects underwent echocardiography accord-
ing to the standardised protocol, and an experienced exam-
iner analysed the digitally stored image using the EchoPac 
software version 4.0.4 (GE Vingmed, Horten, Norway). Left 
ventricular mass was calculated based on the method of 
Devereux et al. and then adjusted for body surface area to 
obtain the left ventricular mass index (LVMI) [19]. Based on 
the transmitral blood flow signal, we measured peak early 
diastolic velocity (E), peak late diastolic velocity (A), and the 
early-to-atrial mitral inflow velocity ratio (E/A). On the basis 
of the tissue Doppler imaging recordings, we measured peak 
early diastolic mitral annular velocity (E’) and the pulmonary 
vein systolic-to-diastolic velocity ratio (S/D). We calculated 
the E/E’ ratio by dividing transmitral E peak by E’ velocity. 
Statistical analysis
For continuous variables, the Shapiro-Wilk test was applied as 
the first step in checking the normality of distribution. Because 
almost none of the continuous variables had normal distribu-
tion, all of them were presented as median and Q1–Q3 quar-
tiles. Categorical variables were shown as a number and per-
centage of observations. Baseline patient characteristics and 
differences between women and men were compared using 
the Mann-Whitney U test and the c2 test. Spearman’s correla-
tion coefficient was used to assess the relationship between 
the inflammatory and rest continuous parameters. The results 
were also shown on scatter plots. Additionally, multifactorial 
models were developed for the logarithmic parameters de-
scribing LVDD. Along with the inflammatory parameters, the 
models took into account other parameters characterising the 
study group (NT-proBNP level, age, systolic blood pressure, 
diastolic blood pressure, heart rate, body mass index, treated 
hypertension, left ventricular internal diameter, ejection frac-
tion, left atrial diameter, and LVMI). 
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A p-value < 0.05 was accepted as statistically significant. 
All the calculations were carried out using STATISTICA soft-
ware version 12.0 (StatSoft, Inc., Tulsa, OK, USA).
RESULTS 
Characteristics of the subjects
The study involved 303 subjects, including 167 (55%) women 
and 136 (45%) men. The men were significantly taller, had 
greater body weight and waist circumference, higher systolic 
blood pressure, greater alcohol intake, and lower heart rate. 
There was no significant difference in hypertension treatment 
between women and men (Table 1). The echocardiographic 
evaluation of the parameters in men revealed greater end- 
-diastolic volume of the left ventricle, thicker interventricular sep-
tum and posterior wall of the left ventricle, larger left atrium, greater 
mass of the left ventricle and lower LVEF. E wave and A wave 
velocity as well as the S/D ratio were greater in women (Table 2). 
In addition, the analysis of the laboratory tests showed that 
women had a significantly higher concentration of NT-proBNP 
and a considerably lower concentration of MPO (Table 3).
The analysis of the influence of inflammatory factors on 
LVDD parameters demonstrated that the plasma concentra-
tion of IL-6 correlated with all the tested parameters of the 
LVDD in men. Moreover, an increase in IL-6 was associated 
with a decrease in the E/A ratio and the E’ velocity and an 
increase in the S/D ratio in men and women (Table 4, Fig. 1). 
Regardless of the sex, a significant positive correlation was 
observed between S/D and the CRP concentration; in women 
an additional positive correlation was noted with the A wave 
and a negative correlation with the E/A ratio. In both women 
and men, no strong correlation existed between the MPO 
concentration and any of the parameters of the LVDD. Age 
significantly correlated with both the inflammatory factors 
(except MPO) and all LVDD parameters. Detailed results ac-
cording to age and sex are presented in Table 4. Regarding 
the multifactorial models, only one model was significant 
(p < 0.001), with R2 = 0.611 for logarithmic parameters of E’. 
This model contained IL-6, age, and heart rate and only 
concerned men (Table 5).
DISCUSSION
Pharmacotherapy has been proven to reduce morbidity and 
mortality only in patients with HFREF. Treatment of isolated 
HFPEF is yet to be determined. Hypertension, the main risk 
Table 1. Characteristics of the participants
Characteristics Women (n = 167) Men (n = 136) p
Anthropometric data:
Age [years] 49.0 (36.1–61.4) 40.1 (32.2–61.7) 0.170
Age < 50 years 80 (58.8) 56 (41.2) 0.286
Age ≥ 50 years 88 (52.7) 79 (47.3)
Height [cm] 164.0 (158.0–168.0) 176.0 (172.0–181.0) < 0.001
Weight [kg] 70.0 (57.0–79.4) 84.0 (74.3–93.4) < 0.001
Body mass index [kg/m2] 26.2 (21.2–30.1) 26.5 (24.4–29.7) 0.056
Waist circumference [cm] 88.0 (74.0–99.0) 96.0 (90.0–104.0) < 0.001
Systolic BP [mmHg] 122.2 (112.1–134.9) 131.2 (121.9–140.9) < 0.001
Diastolic BP [mmHg] 83.8 (76.6–89.3) 85.1 (79–92.2) 0.083
Heart rate [bpm] 74.0 (66.0–81.0) 70.5 (63.0–78.5) 0.045
Questionnaire data:
Current smoking 21 (12.6) 23 (16.9) 0.287
Alcohol use 21 (12.6) 53 (39.0) < 0.001
Hypertension 83 (49.7) 82 (60.3) 0.066
Hypertension treatment 45 (33.1) 60 (35.9) 0.605
Hypertension treatment data:
ACEI or ARB 21 (15.4) 25 (15.0) 0.910
b-blocker 26 (19.1) 41 (24.6) 0.257
Diuretic 21 (15.4) 28 (16.8) 0.755
Calcium channel blocker 13 (9.6) 24 (14.4) 0.203
Aldosterone antagonist 13 (9.6) 12 (7.2) 0.455
a-blocker 1 (0.7) 0 (0.0) 0.499
Values are presented as median (Q1–Q3), or number of subjects (percentage). ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin 
receptor blockers; BP — blood pressure
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factor for heart failure, and its development are associated 
with the disturbed interaction of many factors, among which 
the role of inflammatory markers should be emphasised.
The influence of inflammatory factors on LVDD is a rela-
tively new topic in the literature. The results of the first studies 
to appear on this subject in the last few months have focused 
on both animal and human populations [20–23]. 
The present study evaluated the influence of inflam-
matory factors on the parameters of LVDD in the general 
population, concentrating on men and women separately. 
Moreover, correlation between age, inflammatory markers, 
and LVDD was found; therefore, two age groups were also 
analysed (< 50 and ≥ 50 years old). It was proven that the 
plasma concentration of IL-6 in men weakly correlated with 
all the tested parameters of LVDD, while in women the only 
parameters with which it had no significant correlation were 
peak early diastolic velocity and E/E’. Additionally, only one 
LVDD parameter (E’) for men may be predicted by IL-6, and it 
is also dependent on age and heart rate. These results suggest 
that inflammation, which is associated with an increase in the 
concentration of inflammatory factors, including IL-6, results 
in vascular endothelial dysfunction, myocardial fibrosis, and 
consequently, in LVDD. 
Fang et al. [20] analysed the association between inflam-
matory markers and LVDD in patients with hypertrophic 
cardiomyopathy (HCM). Their study focused on 50 patients 
with HCM and a control group of 20 persons. All subjects 
underwent cardiac magnetic resonance imaging and echo-
cardiography, including an evaluation of LVDD using the 
E/A wave ratio, mitral annular velocity (E’), and the E/E’ ratio. 
In addition, the patients were tested for the concentration 
of 16 selected inflammatory cytokines. The results showed 
significantly higher levels of TNF, IL-6, and serum amyloid P 
component (SAP) in patients with HCM compared to the 
control group. Furthermore, the concentrations of IL-6 and 
IL-4 and monocyte chemotactic protein (MCP-1) correlated 
Table 2. Echocardiographic characteristics of the participants
Characteristics Women (n = 167) Men (n = 136) p
Conventional echocardiography:
Left atrial diameter [mm] 35.0 (32.0–39.0) 38.0 (36–41) < 0.001
LV internal diastolic diameter [mm] 48.0 (45.0–51.0) 52.0 (50–54) < 0.001
Interventricular septum thickness [mm] 9.0 (7.0–10.0) 10.0 (9–11) < 0.001
Posterior wall thickness [mm] 8.0 (7.0–10.0) 10.0 (8–10) < 0.001
LV mass index [g/m2] 78.9 (66.6–93.5) 96.1 (81.9–106.9) < 0.001
LV mass [g] 138.4 (111.0–166.9) 190.7 (160.4–221.7) < 0.001
LV ejection fraction [%] 70.0 (70.0–77.0) 67.0 (62.0–71.0) < 0.001
Doppler data:
E [cm/s] 77.0 (66.0–87.5) 73.5 (59.0–82.3) 0.033
A [cm/s] 64.0 (54.0–77.0) 57.5 (51.0–69.3) 0.003
E/A ratio 1.18 (0.9–1.5) 1.23 (1.0–1.5) 0.603
E’ [cm/s] 11.0 (8.0–14.0) 11.0 (8.0–14.0) 0.894
E/E’ ratio 6.80 (5.9–8.6) 6.55 (5.6–7.8) 0.104
S/D ratio 1.32 (1.13–1.49) 1.20 (0.98–1.43) < 0.001
Values are presented as median (Q1–Q3). A — peak late diastolic velocity; E — peak early diastolic velocity; E’ — peak early diastolic mitral annular 
velocity; E/A — early-to-atrial mitral inflow velocity ratio; E/E’ — ratio of early diastolic velocity to early diastolic mitral annular velocity; LV — left 
ventricular; S/D — pulmonary vein systolic-to-diastolic velocity ratio
Table 3. Biochemical markers in the study population
Characteristics Women (n = 167) Men (n = 136) p
NT-proBNP [pg/mL] 71.5 (48.4–113.0) 40.6 (21.5–70.7) < 0.001
CRP [mg/L] 1.38 (1.00–2.56) 1.05 (1.00–1.79) 0.093
Interleukin 6 [pg/mL] 1.37 (0.99–1.85) 1.30 (0.89–1.91) 0.414
Myeloperoxidase [ng/mL] 34.8 (22.3–65.1) 52.5 (25.5–103.7) < 0.001
Values are median (Q1-Q3). CRP — C-reactive protein; NT-proBNP — N-terminal pro–B-type natriuretic peptide
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with regional fibrosis, while the levels of stromal cell-derived 
factor-1 and MCP correlated with diffuse fibrosis. An asso-
ciation existed between fractalkine and interferon g and left 
ventricular wall thickness. In addition, TNF-a, IL-6, SAP, MCP, 
and IL-10 were associated with LVDD parameters in this study 
population. It was also shown that the white blood cell count 
was significantly elevated in patients with HCM, and this was 
related with diffuse fibrosis and LVDD. Based on these results, 
it was concluded that the concentration of inflammatory 
markers was associated with the progression of HCM, and 
especially with the severity of myocardial fibrosis. In addition, 
it was found that interference with inflammation might limit 
the fibrotic process in patients with HCM. 
Another experimental study assessed the function of the 
autonomic and circulatory system, inflammatory markers, and 
oxidation in two groups of female mice (a group of wild mice 
[n = 14] and a group of mice with leptin deficiency [n = 14]) 
[21]. The  examined animals underwent an assessment of 
metabolic parameters, evaluation of heart function using 
echocardiography, including systolic dysfunction and LVDD 
(isovolumetric time and the E/A ratio) [22], as well as testing 
of autonomic and endocrine system indicators and inflam-
matory and oxidative stress markers. Leptin-deficient animals 
had increased body weight, as well as higher fasting glucose 
and triglycerides compared to wild-type mice. Although the 
left ventricular systolic function was similar in both groups, the 
leptin-deficient mice were characterised by autonomic dys-
function and LVDD. Moreover, the inflammation markers in 
this group were higher. On this basis, the researchers speculate 
that these findings might suggest a relationship between the 
occurrence of LVDD, diabetes, and obesity in women as well 
as a significantly higher risk of cardiovascular complications 
in women compared to men. This may be due to the greater 
impairment of endothelial response in diabetic women, which 
is associated with a reduced beneficial oestrogen effect on 
the cardiovascular system, the promotion of oxidative stress, 
and inflammation. 
Patients with carbohydrate disorders and predictive 
factors for the development of LVDD were also studied by 
Mocan et al. [23]. High-sensitivity CRP, fibrinogen, IL-6, IL-8, 
Table 4. Relationship between inflammatory markers and left ventricular diastolic dysfunction with and without division into age 
groups
CRP MPO IL6 Age
Women Men Women Men Women Men
Age 0.251** 0.035 0.420**
0.289** 0.204* 0.104 –0.015 0.422** 0.416*
E –0.054 0.042 –0.055 –0.008 –0.100 –0.175* –0.492**
–0.0301 –0.1161 –0.1911 0.0121 –0.229*1 –0.2101 –0.486M
0.0162 –0.0342 –0.0382 –0.2132 0.1282 –0.1242 –0.543W
A 0.176* 0.156 0.091 0.038 0.240** 0.244** 0.542**
0.1221 0.389**1 –0.0541 0.1481 0.0851 0.1951 0.455M
0.345**2 0.0932 0.0942 0.0522 0.311**2 0.1772 0.586W
E/A –0.182* –0.099 –0.108 –0.020 –0.235** –0.235** –0.704**
–0.1731 –0.396**1 –0.0441 –0.2191 –0.279**1 –0.299**1 –0.619M
–0.297**2 –0.0332 –0.1122 –0.1352 0.1322 –0.1302 –0.782W
E’ –0.112 –0.87 –0.066 0.038 –0.221** –0.395** –0.782**
–0.0351 –0.275**1 –0.0411 –0.0541 –0.228**1 –0.270**1 –0.720M
0.0052 –0.438**2 –0.0562 –0.0142 –0.1392 –0.360**2 –0.833W
E/E’ 0.085 0.123 0.007 –0.022 0.156 0.203* 0.552**
0.0221 0.0831 –0.0741 0.1051 0.0271 0.0271 0.504 M
0.0932 0.305*2 0.0072 –0.1722 0.280*2 0.1932 0.575W
S/D 0.286** 0.200* 0.080 0.026 0.273** 0.269** 0.477**
0.2071 0.286*1 0.0151 0.0401 0.220*1 0.1461 0.534 M
0.1762 0.0032 0.0032 0.0862 –0.0062 0.1792 0.397W
*p < 0.05; **p < 0.01; IL-6 — interleukin 6; M — men; W — women. Others abbreviations — see Tables 2 and 3
Values represent Spearman’s correlation coefficients. In the first row analysis without age division.
1Analysis for patients aged < 50 years old; 2Analysis for patients aged ≥ 50 years old
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8-iso-prostaglandin F2a, uric acid, glutathione peroxidase, 
and NT-proBNP were determined in patients with metabolic 
syndrome, who had not been previously diagnosed with 
cardiovascular disease (n = 72). This group also underwent 
echocardiography, and their LVDD was assessed. The tests 
identified LVDD in approximately 65.27% of patients. The 
strongest predictors of LVDD development were diastolic 
pressure and the number of metabolic syndrome-defining 
criteria met by the patient. 
In addition, IL-6, high-sensitivity CRP, fibrinogen, and 
NT-proBNP were factors responsible for the development of 
LVDD. However, it should be emphasised that, similarly to 
our study, as indicated by multivariate analysis, IL-6 was the 
only independent prognostic biomarker for LVDD. 
Table 5. Multifactorial models for the logarithmic parameters of E’
B SE(B) T p
Intercept 1.518 0.060 25.360 < 0.001
Interleukin 6 –0.024 0.010 –2.446 0.016
Age –0.006 0.001 –11.887 < 0.001
Heart rate –0.002 0.001 –3.339 0.001
B — regression coefficient; SE(B) — standard error for regression coefficient; T — t statistic test
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Figure 1. Scatter plots indicating significant correlations between inflammatory markers and left ventricular diastolic dysfunction; 
IL-6 — interleukin 6; other abbreviations — see Table 2
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In summary, our study identified in its population 
a moderate relationship between IL-6 and one of the LVDD 
parameters (E’) in men. Univariate analysis revealed a correla-
tion of IL-6 and the majority of LVDD parameters; however, 
after adjustment for age the relationship was not significant.
This observation may suggest a possibility of inflamma-
tory mechanisms related to the development of LVDD. Based 
on this study it could be speculated that interference with 
inflammation might limit the development of LVDD. Due to 
the scarcity of reports on this topic in the literature, further 
extensive studies are needed to evaluate this relationship. 
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WHAT IS NEW?
Pharmacotherapy has been proven to reduce morbidity and mortality only in patients with heart failure with reduced 
ejection fraction. Treatment of isolated heart failure with preserved ejection fraction remains undetermined. Hypertension, 
the main risk factor for heart failure, and its development are associated with the disturbed interaction of many factors, 
among which the role of inflammatory markers should be emphasised. The results of our study suggest that inflamma-
tion, which is associated with an increase in inflammatory markers, including interleukin 6, leads to the onset of left 
ventricular diastolic dysfunction (LVDD), probably via vascular endothelial dysfunction. Moreover, the study identified 
in its population a relationship between the concentration of interleukin 6 and the majority of LVDD parameters. This 
observation may shed new light on the mechanisms related to the development of LVDD. This relationship requires 
further research, which could change our current views on the treatment of heart failure with preserved ejection fraction.
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